Our top pick for
Building a portfolio

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
BioTelemetry, Inc is a diagnostics & research business based in the US. BioTelemetry shares (BEAT) are listed on the NASDAQ and all prices are listed in US Dollars. BioTelemetry employs 1,700 staff and has a trailing 12-month revenue of around USD$414.8 million.
Our top pick for
Building a portfolio
Our top pick for
Beginners
Our top pick for
Active traders
52-week range | USD$31.24 - USD$72.6294 |
---|---|
50-day moving average | USD$71.9617 |
200-day moving average | USD$54.0364 |
Wall St. target price | USD$72 |
PE ratio | 149.9167 |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | USD$0.48 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing BioTelemetry stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of BioTelemetry's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
BioTelemetry's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 150x. In other words, BioTelemetry shares trade at around 150x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
BioTelemetry's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.48. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into BioTelemetry's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
BioTelemetry's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$98.6 million.
The EBITDA is a measure of a BioTelemetry's overall financial performance and is widely used to measure a its profitability.
Revenue TTM | USD$414.8 million |
---|---|
Operating margin TTM | 12.84% |
Gross profit TTM | USD$252.5 million |
Return on assets TTM | 4.71% |
Return on equity TTM | 4.67% |
Profit margin | 4.26% |
Book value | $11.57 |
Market capitalisation | USD$2.5 billion |
TTM: trailing 12 months
There are currently 2.2 million BioTelemetry shares held short by investors – that's known as BioTelemetry's "short interest". This figure is 3.4% up from 2.1 million last month.
There are a few different ways that this level of interest in shorting BioTelemetry shares can be evaluated.
BioTelemetry's "short interest ratio" (SIR) is the quantity of BioTelemetry shares currently shorted divided by the average quantity of BioTelemetry shares traded daily (recently around 1.8 million). BioTelemetry's SIR currently stands at 1.2. In other words for every 100,000 BioTelemetry shares traded daily on the market, roughly 1200 shares are currently held short.
However BioTelemetry's short interest can also be evaluated against the total number of BioTelemetry shares, or, against the total number of tradable BioTelemetry shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case BioTelemetry's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 BioTelemetry shares in existence, roughly 30 shares are currently held short) or 0.0511% of the tradable shares (for every 100,000 tradable BioTelemetry shares, roughly 51 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against BioTelemetry.
Find out more about how you can short BioTelemetry stock.
We're not expecting BioTelemetry to pay a dividend over the next 12 months.
Over the last 12 months, BioTelemetry's shares have ranged in value from as little as $31.24 up to $72.6294. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while BioTelemetry's is 1.3116. This would suggest that BioTelemetry's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
BioTelemetry, Inc., a remote medical technology company, provides remote cardiac monitoring, remote blood glucose monitoring, centralized core laboratory services for clinical trials, and original equipment manufacturing services for healthcare and clinical research customers worldwide. It operates in two segments, Healthcare and Research. The Healthcare segment focuses on the remote cardiac monitoring to identify cardiac arrhythmias or heart rhythm disorders. This segment offers mobile cardiac telemetry services; and event monitoring services, which enable physicians to prescribe wireless event, digital loop event, memory loop event, memory loop event, and non-loop event monitors. It also provides traditional and extended Holter, pacemaker, international normalized ratio, implantable loop recorder, and other implantable cardiac device monitoring services. It serves cardiologists, electrophysiologists, neurologists, and primary care physicians. The Research segment offers laboratory services, such as cardiac monitoring, imaging, scientific consulting, and data management services for drug and medical device trials. Its centralized services comprise electrocardiogram, Holter monitoring, ambulatory blood pressure monitoring, echocardiography, multigated acquisition scan, imaging, protocol development, expert reporting, and statistical analysis. It also provides support services, such as project coordination, setup and management, equipment rental, data transfer, processing, analysis, and 24/7 customer support and site training. The company also focuses on manufacturing, testing, and marketing of cardiac devices and blood glucose monitoring devices, as well as offers contract manufacturing services. BioTelemetry, Inc. was founded in 1994 and is headquartered in Malvern, Pennsylvania. As of February 9, 2021, BioTelemetry, Inc. operates as a subsidiary of Philips Holding USA Inc.
Steps to owning and managing NSE, with 24-hour and historical pricing before you buy.
Steps to owning and managing NPA, with 24-hour and historical pricing before you buy.
Steps to owning and managing NFH, with 24-hour and historical pricing before you buy.
Steps to owning and managing NEP, with 24-hour and historical pricing before you buy.
Steps to owning and managing NEN, with 24-hour and historical pricing before you buy.
Steps to owning and managing NTST, with 24-hour and historical pricing before you buy.
Steps to owning and managing NSYS, with 24-hour and historical pricing before you buy.
Steps to owning and managing NOA, with 24-hour and historical pricing before you buy.
Steps to owning and managing NMM, with 24-hour and historical pricing before you buy.
Steps to owning and managing NMCI, with 24-hour and historical pricing before you buy.